Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen
Board of Directors
Biogen Inc. (NASDAQ: BIIB) today announced that the Board of
Directors has elected Caroline Dorsa as Chair of the Board of
Directors, effective immediately following the Company’s 2023
Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to
take place on June 14, 2023. Ms. Dorsa will succeed Stelios
Papadopoulos, Ph.D., who announced he would not stand for
reelection to the Board at the Annual Meeting.
Dr. Papadopoulos said: “The entire Board has great respect for
Caroline and the tremendous contributions she has made during her
13-year tenure and as Chair of our Audit Committee, where she has
exhibited exceptional judgement, integrity, and dedication.
It has been an honor to serve on the Board of such an important,
purpose-driven company that has delivered numerous breakthrough
medicines and therapies that have improved the lives of patients
all around the world. I’m stepping down knowing that the Board will
be in very good hands under Caroline’s outstanding leadership.”
Ms. Dorsa joined the Biogen Board in 2010. She served as
Executive Vice President and Chief Financial Officer of Public
Service Enterprise Group, Inc., a diversified energy company, from
2009 until her retirement in 2015, and served on its Board of
Directors from 2003 to 2009. Prior to that, she held various
financial and operational positions over her 21 years at Merck
& Co, including Senior Vice President, Global Human Health,
Strategy and Integration, and Vice President and Treasurer.
Ms. Dorsa said: “Stelios has overseen a period of tremendous
growth and change. The Board and Biogen have benefited greatly from
his experience, intelligence, and outstanding leadership.
It is a privilege to be part of such a talented and diverse
Board. I look forward to working with the company leadership to
build on Stelios’s legacy and to continue to deliver meaningful
therapies for patients and value to our shareholders. This is a
dynamic time for Biogen, and I believe the company is well
positioned to deliver long-term sustainable growth.”
Biogen President and Chief Executive Officer Christopher A.
Viehbacher said: “On behalf of everyone at Biogen, I want to
express our deepest appreciation to Stelios for his tireless
dedication and powerful vision to transform Biogen into a global
biotechnology leader. Under his leadership, Biogen has pioneered
transformative medicines including TECFIDERA in multiple sclerosis
and SPINRAZA in spinal muscular atrophy, and advanced science that
led to the co-development of ADUHELM and LEQEMBI in Alzheimer’s
disease. Caroline has deep knowledge of our company and I look
forward to continuing to work with her and the rest of the Board to
help drive growth for shareholders and deliver innovation for the
patients we serve.”
About Biogen
Founded in 1978, Biogen is a leading global biotechnology
company that has pioneered multiple breakthrough innovations
including a broad portfolio of medicines to treat multiple
sclerosis, the first approved treatment for spinal muscular
atrophy, and two co-developed treatments to address a defining
pathology of Alzheimer’s disease. Biogen is advancing a pipeline of
potential novel therapies across neurology, neuropsychiatry,
specialized immunology and rare diseases and remains acutely
focused on its purpose of serving humanity through science while
advancing a healthier, more sustainable and equitable world.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social media –
Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking
statements, relating to: our strategy and plans; potential of, and
expectations for, our commercial business and pipeline programs;
capital allocation and investment strategy; clinical development
programs, clinical trials, and data readouts and presentations;
regulatory discussions, submissions, filings, and approvals; the
potential benefits, safety, and efficacy of our and our
collaboration partners’ products and investigational therapies; the
anticipated benefits and potential of investments, optimization of
the cost structure, actions to improve risk profile and
productivity of R&D pipeline, collaborations, and business
development activities; our future financial and operating results;
2023 financial guidance. These forward-looking statements may be
accompanied by such words as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “potential,” “possible,” “prospect,” “will,” “would,” and
other words and terms of similar meaning. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these
statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including: our dependence on sales from our
products; uncertainty of long-term success in developing,
licensing, or acquiring other product candidates or additional
indications for existing products; failure to compete effectively
due to significant product competition in the markets for our
products; failure to successfully execute or realize the
anticipated benefits of our strategic and growth initiatives;
difficulties in obtaining and maintaining adequate coverage,
pricing, and reimbursement for our products; our dependence on
collaborators, joint venture partners, and other third parties for
the development, regulatory approval, and commercialization of
products and other aspects of our business, which are outside of
our full control; the potential impact of the conflict in Ukraine;
risks associated with current and potential future healthcare
reforms; risks related to commercialization of biosimilars; failure
to obtain, protect, and enforce our data, intellectual property,
and other proprietary rights and the risks and uncertainties
relating to intellectual property claims and challenges; the risk
that positive results in a clinical trial may not be replicated in
subsequent or confirmatory trials or success in early stage
clinical trials may not be predictive of results in later stage or
large scale clinical trials or trials in other potential
indications; risks associated with clinical trials, including our
ability to adequately manage clinical activities, unexpected
concerns that may arise from additional data or analysis obtained
during clinical trials, regulatory authorities may require
additional information or further studies, or may fail to approve
or may delay approval of our drug candidates; the occurrence of
adverse safety events, restrictions on use with our products, or
product liability claims; risks relating to technology failures or
breaches; problems with our manufacturing processes; risks relating
to management and personnel changes, including attracting and
retaining personnel; failure to comply with legal and regulatory
requirements; the risks of doing business internationally,
including currency exchange rate fluctuations; risks relating to
investment in our manufacturing capacity; the direct and indirect
impacts of the ongoing COVID-19 pandemic on our business; risks
relating to the distribution and sale by third parties of
counterfeit or unfit versions of our products; risks relating to
the use of social media for our business; results of operations,
and financial condition; fluctuations in our operating results;
risks related to investment in properties; the market, interest,
and credit risks associated with our investment portfolio; risks
relating to share repurchase programs; risks relating to access to
capital and credit markets; risks related to indebtedness; change
in control provisions in certain of our collaboration agreements;
fluctuations in our effective tax rate; environmental risks; and
any other risks and uncertainties that are described in other
reports we have filed with the U.S. Securities and Exchange
Commission. These statements speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements.
MEDIA CONTACT: |
INVESTOR CONTACT: |
Biogen |
Biogen |
Jack Cox |
Mike Hencke |
+1 210 544 7920 |
+1 781 464 2442 |
public.affairs@biogen.com |
IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024